- Patent Title: Tetrahydrobenzimidazole derivatives as modulators of TNF activity
-
Application No.: US15038287Application Date: 2014-12-08
-
Publication No.: US10093652B2Publication Date: 2018-10-09
- Inventor: Jag Paul Heer , Victoria Elizabeth Jackson , Boris Kroeplien , Fabien Claude Lecomte , John Robert Porter
- Applicant: UCB Biopharma SPRL
- Applicant Address: BE Brussels
- Assignee: UCB BIOPHARMA SPRL
- Current Assignee: UCB BIOPHARMA SPRL
- Current Assignee Address: BE Brussels
- Agency: McDonnell Boehnen Hulbert & Berghoff LLP
- Priority: GB1321744.3 20131209
- International Application: PCT/EP2014/076854 WO 20141208
- International Announcement: WO2015/086513 WO 20150618
- Main IPC: A61K35/28
- IPC: A61K35/28 ; A01N1/02 ; G01N33/569 ; C12N5/0789 ; C07D401/10 ; C07D235/12 ; A61K31/4439
Abstract:
A series of substituted 4,5,6,7-tetrahydrobenzimidazole derivatives, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
Public/Granted literature
- US20160297795A1 Tetrahydrobenzimidazole Derivatives as Modulators of TNF Activity Public/Granted day:2016-10-13
Information query
IPC分类:
